Guri Solum
Overview
Explore the profile of Guri Solum including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I, et al.
Lancet Reg Health Eur
. 2024 Dec;
48:101121.
PMID: 39624496
Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was...
2.
Mukherjee R, Eggesbo L, Wolf A, Kjonstad I, Solum G, Ravussin A, et al.
NPJ Vaccines
. 2024 Nov;
9(1):238.
PMID: 39613759
Heterogeneity in vaccine response, particularly in vulnerable populations like the elderly, represents a significant public health challenge. We conducted an in-depth examination of immune cell profiles before and after SARS-CoV-2...
3.
Wolf A, Bjorlykke K, Orbo H, Bhandari S, Solum G, Kjonstad I, et al.
EBioMedicine
. 2024 Sep;
108:105317.
PMID: 39260039
Background: Understanding cellular responses to SARS-CoV-2 immunisations is important for informing vaccine recommendations in patients with inflammatory bowel disease (IBD) and other vulnerable patients on immunosuppressive therapies. This study investigated...
4.
Wolf A, Ravussin A, Konig M, Overas M, Solum G, Kjonstad I, et al.
JCI Insight
. 2023 May;
8(12).
PMID: 37159281
Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies, including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR)...
5.
Ravussin A, Robertson A, Wolf A, Blix K, Kjonstad I, Solum G, et al.
Lancet Healthy Longev
. 2023 May;
4(5):e188-e199.
PMID: 37148891
Background: Older age is associated with poorer outcomes to COVID-19 infection. The Norwegian Institute of Public Health established a longitudinal cohort of adults aged 65-80 years to study the effects...
6.
Kared H, Wolf A, Alirezaylavasani A, Ravussin A, Solum G, Tran T, et al.
Nat Commun
. 2022 Jul;
13(1):4165.
PMID: 35851055
The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It...
7.
Tryggestad A, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg E, et al.
Prostate
. 2021 Nov;
82(2):245-253.
PMID: 34762317
Background: Patients with high-risk prostate cancer (PC) can experience biochemical relapse (BCR), despite surgery, and develop noncurative disease. The present study aimed to reduce the risk of BCR with a...
8.
Rao S, Solum G, Niederdorfer B, Norsett K, Bjorkoy G, Thommesen L
BMC Cancer
. 2017 Jan;
17(1):68.
PMID: 28109268
Background: The peptide hormone gastrin exerts a growth-promoting effect in both normal and malignant gastrointestinal tissue. Gastrin mediates its effect via the cholecystokinin 2 receptor (CCKBR/CCK2R). Although a substantial part...